FDA Seeks Input on Biologics License Paperwork
Published Date: 7/6/2026
Notice
Summary
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Paperwork Burden for Biologics Makers
If you are a licensed manufacturer of biological products, the FDA estimates there are 371 respondents who will file an estimated 70,946 total annual responses, which together require about 860,170 total burden hours each year. These reporting and recordkeeping requirements come from 21 CFR parts 600-680 and 601 and are tied to Biologics License Applications (BLAs).
Standard Forms and Electronic Filing Rules
The FDA requires use of specific forms for BLAs, including Form FDA 356h, Form FDA 2252, Form FDA 2253, and Form FDA 3674, and permits submission via the Electronic Submission Gateway (ESG) for which respondents must create and maintain a user account. FDA states that using Form FDA 356h helps ensure applications are complete and may avoid delays in review.
Net Annual Response and Hour Adjustments
FDA reports cumulative adjustments that result in an average decrease of 2,168 responses and an average increase of 29,133 burden hours annually for this collection. These adjustments change how much time respondents must spend on their BLA-related submissions each year.
Notify Agents on License Suspension
Under 21 CFR 601.6(a), licensed firms must notify selling agents and distributors if a license is suspended. FDA estimates this third-party disclosure will result in about 20 disclosures (0.33 hours each) totaling roughly 7 hours annually for applicable respondents.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2026-13532, Self-Regulatory Organizations; NYSE American LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Modify the NYSE American Options Fee Schedule Regarding Fees and Rebates Applicable to Manual Transactions
Starting now, NYSE American is changing how it charges fees and gives rebates for manual options trades. Market Makers will see updated fees on non-Penny stocks, and Floor Brokers will get new rebates when they trade with Market Makers on the floor. These changes kick in immediately and could affect how much traders pay or earn during manual transactions.
Next: 2026-13534, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!